An organic electrolytic solution, including a first lithium salt, an organic solvent, and a bicyclic sulfate-based compound represented by Formula 1 below: ##STR00001##
wherein, in Formula 1, each of A1, A2, A3, and A4 is independently a covalent bond, a substituted or unsubstituted C1-C5 alkylene group, a carbonyl group, or a sulfinyl group, wherein both A1 and A2 are not a covalent bond and both A3 and A4 are not a covalent bond.

A lithium battery includes a cathode including a cathode active material, an anode including an anode active material, and an organic electrolytic solution between the cathode and the anode. The organic electrolytic solution includes a first lithium salt, an organic solvent, an oligomer compound, and a bicyclic sulfate-based compound represented by Formula 1 below: ##STR00001## wherein, in Formula 1, each of A.sub.1, A.sub.2, A.sub.3, and A.sub.4 is independently a covalent bond, a substituted or unsubstituted C.sub.1-C.sub.5 alkylene group, a carbonyl group, or a sulfinyl group, in which both A.sub.1 and A.sub.2 are not a covalent bond and both A.sub.3 and A.sub.4 are not a covalent bond.

A lithium battery includes a cathode including a cathode active material, an anode including an anode active material, and an organic electrolytic solution between the cathode and the anode. The organic electrolytic solution includes a first lithium salt, an organic solvent, an oligomer compound, and a bicyclic sulfate-based compound represented by Formula 1 below: ##STR00001## wherein, in Formula 1, each of A.sub.1, A.sub.2, A.sub.3, and A.sub.4 is independently a covalent bond, a substituted or unsubstituted C.sub.1-C.sub.5 alkylene group, a carbonyl group, or a sulfinyl group, in which both A.sub.1 and A.sub.2 are not a covalent bond and both A.sub.3 and A.sub.4 are not a covalent bond.

The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.

The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.

The present application belongs to the technical field of new energy, in particular to a non-aqueous electrolyte for a lithium ion battery and a lithium ion battery. The non-aqueous electrolyte for a lithium ion battery comprises a non-aqueous organic solvent, a lithium salt, and a spiro compound represented by Structural Formula 1. The compound represented by Structural Formula 1 has the characteristic of sulfonate additives to improve high-temperature storage performance of battery, and also has the characteristic of sulfate additives to improve high-temperature cycle performance of battery. A passivation film is deposited on the surface of positive electrode, and functional group X is further crosslinked to make the coated passivation film more compact and stable, which can effectively improve the electrochemical performance of the electrode, the storage performance and self-discharge performance of the battery.

##STR00001##

The present invention relates to novel compounds of formula (I) or formula (Ia)

##STR00001##

pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.

The present invention relates to novel compounds of formula (I) or formula (Ia)

##STR00001##

pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.

Compounds of the formula I

##STR00001## in which X.sup.1, X.sup.2, X.sup.3, X.sup.4, R.sup.1, R.sup.2, R.sup.3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Compounds of the formula I

##STR00001## in which X.sup.1, X.sup.2, X.sup.3, X.sup.4, R.sup.1, R.sup.2, R.sup.3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.